Fenfluramine diminishes NMDA receptor-mediated seizures via its mixed activity at serotonin 5HT2A and type 1 sigma receptors
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
// María Rodríguez-Muñoz 1 , Pilar Sánchez-Blázquez 1 and Javier Garzón 1 1 Neuropharmacology, Department of Translational Neurosciences, Cajal Institute, CSIC, Madrid E-28002, Spain Correspondence to: Javier Garzón, email: jgarzon@cajal.csic.es Keywords: fenfluramine; seizures; glutamate N-methyl-D-aspartate receptor; type 1 sigma receptor; HINT1 protein Received: January 04, 2018 Accepted: April 03, 2018 Published: May 04, 2018 ABSTRACT Fenfluramine exhibits antiepileptic properties and thus diminishes epileptiform discharges in experimental animal models of Dravet syndrome. Fenfluramine is metabolized into norfenfluramine in vivo , which shows greater affinity and agonist activity at serotonin 5HT2 receptors (5HT2R) than fenfluramine. In this study, we found that fenfluramine and norfenfluramine disrupted the regulatory association of the sigma 1 receptor (σ1R) with NR1 subunits of glutamate N -methyl-D-aspartate receptors (NMDAR), an effect that was also produced by σ1R antagonists such as S1RA and prevented by σ1R agonists such as PPCC. The antagonists removed σ1R bound to NMDAR NR1 subunits enabling calcium-regulated calmodulin (CaM) to bind to those subunits. As a result, CaM may inhibit calcium permeation through NMDARs. The serotoninergic activity of fenfluramine at 5HT2AR, and likely also at 5HT2CR, collaborated with its activity at σ1Rs to prevent the convulsive syndrome promoted by NMDAR overactivation. Notably, fenfluramine enhanced the inhibitory coupling of G protein-coupled receptors such as 5HT1AR and cannabinoid type 1 receptor with NMDARs, thus allowing the more effective restrain of NMDAR activity. Thus, fenfluramine circumvents the negative side effects of direct NMDAR antagonists and may improve the quality of life of subjects affected by such proconvulsant dysfunctions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
CB1 Cannabinoid Receptors and On-Demand Defense Against Excitotoxicity
Marsicano, G., Goodenough, S., Monory, K., Hermann, H., Eder, M., Cannich, A., Azad, S. C., Cascio, M. G., Gutiérrez, S. O., van der Stelt, M., et al. (2003) · Science · doi:10.1126/science.1088208 · Cited by 1,208 · cited 1×
“Indeed, the endocannabinoid system sequesters silent NMDARs via CB1Rs and diminishes the pool of NMDARs that are ready for activation [63, 21, 64], and fenfluramine indirectly promotes this activity.”
BackgroundRothman, R. B., Baumann, M. H., Savage, J. E., Rauser, L., McBride, A., Hufeisen, S. J., & Roth, B. L. (2000) · Circulation · doi:10.1161/01.cir.102.23.2836 · Cited by 722
Serotonin 5-HT1A Receptors Regulate NMDA Receptor Channels through a Microtubule-Dependent Mechanism
Yuen, E. Y. (2005) · Journal of Neuroscience · doi:10.1523/jneurosci.1187-05.2005 · Cited by 225 · cited 3×
“The activity of glutamate NMDARs falls under the negative influence of some G protein-coupled receptors (GPCRs) including the cannabinoid type 1 receptor (CB1R) [21], the acetylcholine type 1 muscarinic receptor [22], the serotonin 5HT1A receptor [23], the adrenergic α1 and α2 receptors [24], the dopamine D3 and D4 re…”
BackgroundSuccessful use of fenfluramine as an add‐on treatment for Dravet syndrome
Ceulemans, B., Boel, M., Leyssens, K., Van Rossem, C., Neels, P., Jorens, P. G., & Lagae, L. (2012) · Epilepsia · doi:10.1111/j.1528-1167.2012.03495.x · Cited by 210 · cited 1×
“com Fenfluramine (3-trifluoromethyl-N-ethylamphetamine), originally recognized as an appetite suppressant in the mid-1960s [14], was used as an addon drug and demonstrated to be a potent antiepileptic drug in Dravet syndrome as 70% of the children were seizure-free for more than 1 year [15, 16].”
MethodRegulation of NMDA Receptors by Dopamine D4Signaling in Prefrontal Cortex
Wang, X., Zhong, P., Gu, Z., & Yan, Z. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-30-09852.2003 · Cited by 159 · cited 1×
“The activity of glutamate NMDARs falls under the negative influence of some G protein-coupled receptors (GPCRs) including the cannabinoid type 1 receptor (CB1R) [21], the acetylcholine type 1 muscarinic receptor [22], the serotonin 5HT1A receptor [23], the adrenergic α1 and α2 receptors [24], the dopamine D3 and D4 re…”
BackgroundYuen, E. Y., Jiang, Q., Chen, P., Feng, J., & Yan, Z. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m801713200 · Cited by 125
Cited by
The Molecular Function of σ Receptors: Past, Present, and Future
Schmidt, H. R., & Kruse, A. C. (2019) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2019.07.006 · Cited by 177
Vavers, E., Zvejniece, L., & Dambrova, M. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106771 · Cited by 30
Pluripotential GluN1 (NMDA NR1): Functional Significance in Cellular Nuclei in Pain/Nociception
McNearney, T. A., & Westlund, K. N. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713196 · Cited by 9
Metadata
- Authors
- Rodríguez-Muñoz, M., Sánchez-Blázquez, P., & Garzón, J.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2018-05-04
- Volume
- 9
- Issue
- 34
- Pages
- 23373-23389
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2799540341
- Cited by
- 47
- References
- 6
- FWCI
- 1.57
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.